Immunicum AB's overall stock score reflects significant financial struggles, characterized by persistent losses and negative cash flow trends. Although technical indicators show positive momentum, valuation metrics remain weak, with a negative P/E ratio and no dividend yield. The lack of earnings call insights or corporate events further limits the assessment.

Immunicum AB (IMMU) vs. iShares MSCI Sweden ETF (EWD)

Market Cap

kr393.24M

Dividend YieldN/A

Average Volume (3M)43.34K

Price to Earnings (P/E)―

Beta (1Y)0.76

Revenue GrowthN/A

EPS Growth21.85%

CountrySE

Employees28

SectorHealthcare

Sector Strength42

IndustryBiotechnology

Share Statistics

EPS (TTM)-0.60

Shares Outstanding52,084,580

10 Day Avg. Volume77,244

30 Day Avg. Volume43,341

Financial Highlights & Ratios

PEG Ratio-0.20

Price to Book (P/B)0.58

Price to Sales (P/S)0.00

P/FCF Ratio-4.63

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

Immunicum AB Business Overview & Revenue Model

Company DescriptionImmunicum AB is a biotechnology company focused on developing novel immune therapies for the treatment of various cancer types. The company operates within the life sciences sector and is dedicated to leveraging its proprietary technology platforms to create innovative solutions that enhance the body's ability to recognize and combat cancer. Its core product offerings are centered around allogeneic dendritic cell-based therapies aimed at improving patient outcomes in oncology.

How the Company Makes MoneyImmunicum AB generates revenue through the development and commercialization of its proprietary immune therapies. The company's primary revenue stream comes from partnerships and collaborations with larger pharmaceutical and biotechnology firms that are interested in co-developing or licensing its technology. These partnerships often involve milestone payments and royalties based on the success and commercialization of the therapies. Additionally, Immunicum may receive funding from grants or governmental support for innovative research in immuno-oncology. The company’s revenue model is heavily reliant on the successful progression of its therapies through clinical trials and subsequent market approval.

Immunicum AB Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	3.41M	28.49M	3.00M	6.00K	0.00	16.67M
Gross Profit	1.79M	28.49M	-1.85M	-1.84M	-1.77M	15.03M
EBITDA	-120.68M	-97.85M	-128.67M	-128.28M	-84.25M	-43.22M
Net Income	-128.40M	-101.62M	-136.99M	-136.69M	-92.47M	-135.71M
Balance Sheet
Total Assets	398.55M	755.95M	620.39M	720.98M	728.66M	303.83M
Cash, Cash Equivalents and Short-Term Investments	393.36M	120.78M	41.85M	155.31M	167.64M	296.81M
Total Debt	850.00K	24.49M	78.16M	36.98M	35.04M	850.00K
Total Liabilities	21.65M	51.23M	105.95M	64.24M	67.57M	31.05M
Stockholders Equity	376.90M	704.73M	514.44M	656.74M	661.09M	272.78M
Cash Flow
Free Cash Flow	-81.51M	-164.58M	-121.43M	-139.39M	-57.09M	-146.62M
Operating Cash Flow	-79.67M	-162.76M	-109.33M	-138.03M	-56.63M	-145.81M
Investing Cash Flow	-1.58M	-442.00K	-12.32M	-1.36M	157.30M	-251.00K
Financing Cash Flow	61.51M	242.10M	8.19M	127.03M	50.90M	756.00K

Immunicum AB Technical Analysis

Technical Analysis Sentiment

Positive

Last Price6.77

Price Trends

50DMA

5.63

Positive

100DMA

6.36

Positive

200DMA

7.48

Positive

Market Momentum

MACD

0.55

Negative

RSI

62.51

Neutral

STOCH

61.32

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IMMU, the sentiment is Positive. The current price of 6.77 is above the 20-day moving average (MA) of 6.26, above the 50-day MA of 5.63, and below the 200-day MA of 7.48, indicating a bullish trend. The MACD of 0.55 indicates Negative momentum. The RSI at 62.51 is Neutral, neither overbought nor oversold. The STOCH value of 61.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:IMMU.

Immunicum AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (50)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMMU	54 Neutral	kr393.24M	―	-18.79%	―	―	21.85%
Sector *	50 Neutral	kr5.29B	11.97	-82.66%	9.67%	36.04%	27.80%
XBRANE	47 Neutral	€386.11M	―	-47.73%	―	45.52%	93.35%
XINT	43 Neutral	kr282.96M	―		―	5303.85%	55.59%
IVACC	42 Neutral	kr320.36M	―	-24.61%	―	47.06%	33.86%
ISOFOL	36 Underperform	kr236.75M	―	-54.29%	―	-100.00%	-17.35%
GUARD	32 Underperform	€334.78M	―	-205.65%	―	―	24.25%

* Healthcare Sector Average

Performance Comparison

SE:IMMU

Immunicum AB

7.55

-0.91

-10.76%

SE:GUARD

Guard Therapeutics International AB

16.60

-11.59

-41.12%

SE:ISOFOL

Isofol Medical AB

0.88

0.24

37.99%

SE:IVACC

Intervacc AB

0.94

-1.79

-65.54%

SE:XBRANE

Xbrane Biopharma AB

0.25

>-0.01

-0.79%

SE:XINT

Xintela AB

0.43

0.15

53.99%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 25, 2025